Find Academic Supervisors

Veerle Foulon serves as full professor and dean of the Faculty of Pharmaceutical Sciences at KU Leuven, Belgium. She leads the Unit Clinical Pharmacology and Pharmacotherapy within the Department of Pharmaceutical and Pharmacological Sciences. Her institutional leadership roles include membership in the University Council, Academic Council, and Special Academic Council as dean, alongside positions in the Board for Alumni Relations and Biomedical Sciences Group Management. Leuven Centre for Health Humanities Leuven Interdisciplinary Centre for Meaning and Lived Religion LC&Y - KU Leuven Institute for Child and Youth LIVO – KU Leuven Institute for Educational Research LKI - KU Leuven Cancer Institute Her research centers on pharmaceutical care, interdisciplinary collaboration, patient-centered care, and rational pharmacotherapy. Key focus areas include medication safety during pregnancy through the BELpREG registry, antimicrobial stewardship in Ethiopian healthcare settings, and person-centered medication optimization for elderly patients in nursing homes. She emphasizes real-world data collection and interdisciplinary approaches to address critical gaps in medication safety for vulnerable populations. Analysis of her recent publications reveals dominant themes in pregnancy medication safety (particularly via the BELpREG cohort), nursing home medication pathways, and antimicrobial resistance interventions. Her work consistently involves large-scale international collaborations across Europe and Ethiopia, addressing systemic challenges in pharmaceutical care through mixed-methods designs and registry-based studies. As principal investigator on major funded projects extending to 2028—including antimicrobial resistance initiatives in Ethiopia and pregnancy medication safety studies—she directs substantial research grants. Her leadership in interdisciplinary consortia drives innovation in medication optimization, though specific doctoral advisees are not documented in the provided materials. Current projects demonstrate strong translational focus with direct clinical implementation pathways. Embedded within multiple Leuven research institutes, she fosters cross-disciplinary collaborations through the BELpREG consortium and antimicrobial stewardship networks. Her work actively involves partnerships with Ethiopian tertiary hospitals, European pregnancy registries, and Belgian nursing home networks to develop and implement evidence-based pharmaceutical care models.

• Pharmaceutical Care
• Interdisciplinary Collaboration
• Patient-Centered Care
• +5 more

Jean-Michel Dogné is a full Professor at the Faculty of Medicine, University of Namur, where he leads research in clinical pharmacology and toxicology. He is affiliated with several key research centers including the Namur Medicine & Drug Innovation Center, the Namur Thrombosis and Hemostasis Center, and the Namur Nanosafety Center. His work is integral to the Namur Research Institute for Life Sciences and he actively contributes to EU-level pharmacovigilance through his role in the EMA's PRAC committee. Education: Doctor of Pharmacy, Université de Liège (2000), Thesis: Drug design and development His research focuses on anticoagulant therapy, thrombosis, drug safety, and personalized medicine , with strong emphasis on clinical applications in cancer and infectious diseases. He has led major projects such as COVILAB (on COVID-19) and studies on BCR-ABL inhibitors in leukemia. His work often involves systematic reviews, meta-analyses, and biomarker discovery, contributing to evidence-based medicine. The 15 most recent publications reflect a sustained focus on thrombosis in oncology, pharmacovigilance, anticoagulants, and pandemic research , with increasing integration of regulatory science and model-informed drug development. His work spans clinical trials, laboratory investigations, crystallography, and public health policy , demonstrating a multidisciplinary approach to pharmaceutical innovation. Scientific Awards: Prix Léo Pharma Cancer & Thrombosis (2017) Jean-Michel Dogné has supervised over 40 students and researchers, contributing significantly to training the next generation of clinical pharmacologists. He has secured numerous national and international grants, particularly in the areas of drug safety and thrombosis. His collaborative network is extensive, involving institutions across Europe and participation in EU-level regulatory bodies. He is a key member of the Clinical Pharmacology Research Group and leads major initiatives such as the MP-EMA project. His team operates within state-of-the-art facilities at the University of Namur, focusing on translational research from bench to bedside.

• Clinical Pharmacology
• Pharmacovigilance
• Thrombosis and Hemostasis
• +7 more

Gregory Ehx is a Researcher at the University of Liège's GIGA institute, specifically within the GIGA-I3 (Infection Immunity and Inflammation) research unit of the Faculty of Medicine. He leads the Translational Immunology and Leukemia research team in the Hematology Laboratory, focusing on understanding immune recognition of acute myeloid leukemia (AML) cells and developing novel immunotherapies. Dr. Ehx's research centers on how leukemia cells are recognized by immune cells and how they escape immune surveillance. His team studies the interaction between T cells and malignant cells, particularly focusing on MHC-presented peptides and immuno-inhibitory molecules like PD-L1 and CD47 expressed by AML cells. Key research areas include: Development of cancer immunotherapies for permanent leukemia eradication Maximizing immune recognition of chemotherapy-surviving cancer cells Identification of tumor-specific immunogenic peptides Understanding mechanisms of chemotherapy resistance His publication record demonstrates significant contributions to cancer immunology, with a focus on proteogenomics and computational approaches to identify actionable tumor antigens. Recent work has revealed how endogenous retroelements generate immunogenic peptides in AML and how autophagy affects immune recognition of cancer cells treated with 5-azacytidine. Scientific recognition includes: FNRS Research associate mandate (2023) Comte de Launoit Prize Dr. Ehx secured funding through the FNRS Research associate program to pursue his ambitious research program on developing vaccines targeting chemotherapy-resistant AML cells. His work on the BamQuery computational tool has enabled identification of tumor-specific MHC peptides, forming the basis for potential cancer vaccine development. His research has implications beyond AML, potentially benefiting treatment of other cancers including colon, lung, and breast cancer. The researcher leads his team within the Hematology Laboratory at GIGA, building on collaborations with researchers at the Institute for Research in Immunology and Cancer (IRIC) in Canada and other international partners. His laboratory combines wet-lab immunology with computational approaches to tackle the challenge of cancer immunotherapy.

• Translational Immunology
• Leukemia Research
• Acute Myeloid Leukemia
• +5 more

Pierre Bulpa is an active researcher with expertise in hematology, pulmonary medicine, and critical care, focusing on thrombotic complications in severe COVID-19 and lung transplantation. His work intersects with the UN Sustainable Development Goals related to health and well-being (SDG 3) and innovation (SDG 9). Collaborations span international institutions, particularly in hemostasis and respiratory disease research. Key research areas: Thrombosis in critically ill patients, lung transplantation, methadone's role in transplant outcomes, and diagnostic algorithms for pulmonary aspergillosis. Recent publications (2020–2023) emphasize longitudinal hemostasis disturbances in COVID-19, validated biomarkers, and data-driven clinical insights. Collaborations include multidisciplinary teams across Belgium and France, with contributions to clinical guidelines.

• Hematology
• Pulmonary Medicine
• Transplantation
• +3 more

Jonathan Douxfils is a Professor at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Thrombosis and Hemostasis Center. His expertise lies in pharmacology, thrombosis, and anticoagulant therapies. He holds a Pharm.D. and Ph.D. from the University of Namur and a Master of Pharmacy from Université Catholique de Louvain. Key roles include CEO of Qualiblood, Co-Chairman of the International Society on Thrombosis and Hemostasis's SSC Control of Anticoagulation, and Pharmacovigilance Expert at the Federal Agency of Medicines and Health Products. His research focuses on anticoagulant safety, thrombosis risk assessment, and innovative diagnostic tools like the DOAC Dipstick. Notable awards include the Alfers Prize 2022, Eberhard F. Mammen Young Investigator Award 2019, and multiple recognition in hemostasis research. He leads projects such as NucleoGlio (glioblastoma diagnostics) and GT4HEALTH (gene therapy research). He has supervised 19 thesis works and contributed to over 436 research outputs. His work aligns with UN SDGs in health and innovation.

• Hematology
• Pharmacology
• Thrombosis Research
• +3 more

Liesbeth Lewi serves as an Associate Professor at KU Leuven's Faculty of Medicine within the Department of Development and Regeneration. She holds dual affiliations with the Woman and Child unit at UZ Leuven (Herestraat 49, box 7003) and Leuven.IRD - KU Leuven Institute for Rare Diseases. Her institutional roles include membership on the Council of the Faculty of Medicine and the Council of the Department of Development and Regeneration as senior academic staff. Her research focuses on high-risk twin pregnancies, particularly selective fetal growth restriction in monochorionic twins, placental pathology, and hemolytic disease management. Current leadership includes the Twin Growth Project (2022-2027), Outcomes of Monochorial Diamniotic Twin Pregnancies (2025-2029), and CONTRAST initiative (2023-2024). Her methodology integrates international multicenter cohort studies, ultrasound innovation, and systematic reviews of perinatal interventions. Analysis of her 2025 publications reveals dominant themes in obstetric ultrasound standardization, twin placental pathophysiology, and evidence-based management of fetal growth disorders. Key trends include international guideline development (ISUOG), Doppler flow analysis for predicting adverse outcomes, and novel echocardiography techniques for twin surveillance. Her teaching portfolio encompasses advanced problem-solving courses in gynecology and obstetrics (E0J61A-E0J71A), evidence-based medicine (E0AA5A), and clinical research methodology (E0C63B) across KU Leuven's medical curriculum. Laboratory and clinical operations center on the Woman and Child unit's fetal medicine research infrastructure, with active collaboration in Leuven.IRD's rare disease networks. Current projects investigate placental vascular anastomoses, umbilical cord insertion pathologies, and postpartum hemorrhage interventions through interventional radiology.

• Maternal-Fetal Medicine
• Twin Pregnancy Research
• Fetal Growth Restriction
• +4 more

Daniel Peralta Cámara is a Postdoctoral Researcher at Ghent University's Faculty of Engineering and Architecture, Department of Information Technology (EA05). His work spans Machine Learning , Bioinformatics , High Performance Computing , and Biometrics , with a focus on Single-Cell Data Analysis , Image Cytometry , and Missing Value Handling . Affiliation: Ghent University Academic Rank: Researcher Research Disciplines: Data Mining, Parallel Computing, Bioinformatics, High Performance Computing His research designs scalable machine learning frameworks for biological and engineering applications, including SCIP for morphological profiling and MSDeepAMR for antimicrobial resistance prediction. He explores advanced techniques like Polar Encoding for missing data and Fuzzy Rough Sets for classification uncertainty, contributing to one-class classification and novelty detection through Python libraries like Fuzzy-rough-learn 0.2 . Key Trends: Hybrid CNN-LSTM for sports analytics Time-series feature selection in healthcare UWB/IMU wearable integration for animal monitoring Dr. Peralta supervises PhD candidates like Maxim Lippeveld (2025) and Oliver Urs Lenz (2023). His collaborations span Ghent University researchers including Eli De Poorter , Chris Cornelis , and Yvan Saeys . Applications: Badminton strategy analysis Goat activity classification White blood cell identification

• Machine Learning
• Bioinformatics
• High Performance Computing
• +5 more

Isabelle Michaux is a researcher at Catholic University of Louvain's School of Medicine, Department of Anesthesiology and Critical Care, with significant contributions to hemostasis research and critical care medicine. Her work spans thrombosis monitoring in critical illness, cardiac surgery complications, and infectious disease management, particularly during the COVID-19 pandemic. Her primary research focuses on hemostasis disturbances in critical care settings , with expertise in thrombosis biomarkers (D-dimer, fibrin monomer), coagulopathy in viral infections, and blood product optimization for surgical patients. Recent work examines vasopressor effects on renal oxygenation and left ventricular thrombus formation in cardiomyopathies. Her research integrates clinical observations with laboratory hemostasis parameters to improve outcomes in critically ill patients. Analysis of her publication trends reveals a strong emphasis on translational hemostasis research , evolving from COVID-19 coagulopathy studies (2020-2021) to broader surgical complication prevention (2023-2024). Key thematic areas include thrombosis prediction in critical illness, antimicrobial stewardship in viral infections, and cardiac complications in transplantation medicine. Her scholarly impact is reflected in a Scopus h-index of 74 with significant citation metrics, including 38 citations for her seminal work on COVID-19 hemostasis disturbances. Her research has been referenced in clinical guidelines and garnered attention across X (formerly Twitter) with over 100 posts and 148 Mendeley readers. Dr. Michaux maintains active collaborations across European institutions, particularly with University Hospital Center teams. Her current research network focuses on surgical complication prevention, with projects spanning cardiac surgery blood management, lung transplantation outcomes, and critical care nephrology. She contributes to antimicrobial stewardship through surveillance studies of viral infections and hospital epidemiology.

• Hemostasis and Thrombosis
• Critical Care Medicine
• Cardiac Surgery Complications
• +3 more

Christina Campo, PhD, is a researcher affiliated with the Faculty of Psychology and Educational Sciences in Brussels, Belgium. Her work intersects medical research and genetic studies, particularly focusing on hematological disorders and their molecular underpinn'the faculty affiliation suggests broader academic engagement. Her research includes contributions to understanding the genetic links between immunoglobulin light-chain amyloidosis and multiple myeloma, as evidenced by her 2014 publication in Leukemia . While her specific role within the faculty is not detailed, her research output highlights cross-disciplinary expertise in medicine and genetics. As of the provided data, Christina Campo has not disclosed email contact information or scientific awards. Her academic activities are primarily reflected in her single peer-reviewed publication, which explores the genetic basis of blood-related diseases.

• Medicine
• Genetics
• Hematology
• +3 more

Kristien Wouters is a clinical doctor and researcher affiliated with the Institute of Tropical Medicine Antwerp. She works in the HIV/STI-clinic, providing care for patients living with HIV/AIDS and STIs, and coordinates the 'Helpcenter,' a low-threshold center for HIV/STI testing focusing on high-risk groups like migrants and men who have sex with men. Her primary role involves secondary HIV prevention through diagnosis and counseling, alongside primary prevention efforts. She holds a Master's in Medicine from the University of Antwerp and completed a Tropical Medicine specialization at the Institute of Tropical Medicine (2001–2002). Research Focus: Her work emphasizes public health interventions in HIV/STI prevention, epidemiology of antibiotic-resistant pathogens like Mycoplasma genitalium, and healthcare access for marginalized populations. She also investigates outcomes in corneal transplantation and quality-of-life issues in hematological disorders. Recent Research Trends: Recent studies address online self-sampling for HIV/STI testing, barriers to PrEP use among migrants, and antibiotic resistance patterns in bacterial STIs. Her publications span peer-reviewed journals like BMJ Open and Sexually Transmitted Infections . Affiliations & Roles: She serves as Chair of Viva Africa, an external organization. Her work bridges clinical practice, research, and public health advocacy, particularly in Belgium and tropical medicine contexts. Labs/Teams: Active in interdisciplinary teams focused on infectious disease control and global health equity, coordinating multicenter trials and community-based screening initiatives.

• HIV/AIDS
• Sexually Transmitted Infections (STIs)
• Public Health
• +6 more

Niels Vandewalle is an active researcher at the Vrije Universiteit Brussel (VUB), affiliated with the Basic (bio-) Medical Sciences department within the Faculty of Medicine and Pharmacy. His work focuses on oncology, immunology, and hematological malignancies, particularly Acute Myeloid Leukemia (AML) and Multiple Myeloma. He leads projects on AXL targeting using single-domain antibodies and small molecule inhibitors, with applications in diagnosis and therapy. Vandewalle has supervised research by Kim De Veirman and collaborates extensively with teams in Belgium and internationally. Research interests include tumor microenvironment dynamics, immune evasion mechanisms, and drug resistance in cancer. His recent studies explore adrenergic signaling's role in myeloma progression and the therapeutic potential of anti-CD40 agonists in activating dendritic cells. Vandewalle has received the Best Poster Presentation award (2024) and contributed to datasets published in high-impact repositories like Zenodo and NCBI GEO. He actively participates in academic events, organizing charity quizzes and PhD symposiums. His projects (e.g., ANI400 and FWOSB110) emphasize translational research, aiming to bridge basic science and clinical applications in leukemia treatment.

• Hematology
• Oncology
• Immunology
• +6 more

Grégoire Wieërs is a Researcher at the University of Namur's Department of Clinical Pharmacology and Toxicology. He holds a Doctorate in Medicine (specializing in General Internal Medicine) and a PhD in Biomedical and Pharmaceutical Sciences from Université catholique de Louvain. His work contributes to UN Sustainable Development Goals, focusing on healthcare sustainability and antibiotic resistance. Education: Doctor in Medicine, specialist in General Internal Medicine PhD in Biomedical and Pharmaceutical Sciences (Genetics and Immunology) Doctor of Pharmacy from the de Duve Institute, Université catholique de Louvain Research Interests: Wieërs' work spans clinical pharmacology, infectious diseases, and sustainable healthcare. He leads projects on antibiotic resistance in gut microbiota, multidisciplinary Down syndrome consultations, and integrating UN Sustainable Development Goals into medical education. His studies often involve collaborations in immunology, virology, and global health policy. Grants & Projects: PI of projects on sustainable development in healthcare (2020–present) Antibiotic resistance in gut microbiota (2019–present) Multidisciplinary consultation for adults with Down syndrome (2023–present) Activities: He chairs Belgium's Bioethics Consultation Committee (2023–2027) and serves as a peer reviewer for journals like Pilot and Feasibility Studies . Media engagements include discussions on hospital sustainability and ecological transitions in healthcare. Lab/Teams: Clinical Pharmacology Research Group (supervisor), focusing on anticoagulant therapies and drug efficacy.

• Clinical Pharmacology
• Antibiotic Resistance
• Sustainable Healthcare
• +3 more

Julie Vassart is a Researcher at the University of Namur's Namur Research Institute for Life Sciences and Clinical Pharmacology Research Group. Her work focuses on anticoagulant therapy monitoring, particularly Direct Oral Anticoagulants (DOACs), with active involvement in multiple national and international projects including the BIOCOAG initiative and FXI(a) inhibitor management studies. Her educational background includes: Master in Pharmaceutical Sciences (2022), University of Namur Dr. Vassart's research centers on developing and validating rapid diagnostic tools for anticoagulant monitoring, with emphasis on DOAC Dipstick accuracy in perioperative settings and novel anticoagulants like asundexian. Her work bridges clinical pharmacology, hematology, and analytical chemistry to improve patient safety during anticoagulation therapy. Current projects investigate intrinsic pathway inhibitors and real-time anticoagulant level assessment. Recent publications demonstrate a clear trend toward point-of-care anticoagulant monitoring solutions, with significant contributions to expert consensus guidelines for DOAC testing. Her research spans method validation against gold-standard techniques (UHPLC-MS/MS), clinical applicability in surgical contexts, and novel anticoagulant impact on coagulation pathways. Scientific recognition includes: Travel award (2024) for conference participation She actively contributes to 3 major research projects: the long-running BIOCOAG project (since 2011) assessing anticoagulation control biology, the FXI(a) inhibitors PhD project (2022–present), and collaborative studies with international consortia. Her work is presented regularly at premier hemostasis conferences including EuroThrombosis and the Belgian Society on Thrombosis and Haemostasis meetings. Dr. Vassart operates within the Clinical Pharmacology Research Group at the Namur Thrombosis and Hemostasis Center (NTHC), which specializes in anticoagulant pharmacology, coagulation assay development, and thrombosis risk assessment using advanced laboratory techniques.

• Anticoagulants
• Direct Oral Anticoagulants (DOACs)
• Thrombosis and Hemostasis
• +3 more

Laure Morimont is a Researcher at the Namur Research Institute for Life Sciences, part of the Clinical Pharmacology and Toxicology Research Unit. Her research focuses on thrombosis, coagulation disorders, and the effects of hormonal therapies and contraceptives on blood clotting. She contributes to projects like the COVILAB initiative on SARS-CoV-2 and the HIC Project evaluating hormone-induced coagulopathy. Morimont has received awards including the 2021 Best Oral Presentation and the 2020 Belgian MedTech Program recognition. Her work spans clinical pharmacology, venous thromboembolism risk assessment, and coagulation testing innovations. Key Projects: Clinical Pharmacology Research Group (2022–present) COVILAB: SARS-CoV-2 investigations (2020–present) HIC Project: Hormone-induced coagulopathy evaluation (2019–2023) Research Interests: Thrombin generation and anticoagulant efficacy Risk assessment of hormonal therapies Coagulopathy in pregnancy and cancer patients Her articles emphasize anticoagulant pharmacodynamics, contraceptive safety, and clinical diagnostic tools like the DOAC Dipstick. Morimont actively collaborates internationally and presents at conferences such as the ISTH Congress. She also leads studies on thrombosis prediction models and coagulation assay standardization.

• Clinical Pharmacology
• Thrombosis
• Coagulation Disorders
• +3 more

Nicolas Debortoli is an evolutionary geneticist focused on molecular adaptation mechanisms in asexual organisms, particularly bdelloid rotifers and freshwater invertebrates. His research examines genetic mixing, desiccation resistance, and environmental DNA applications for biodiversity monitoring. He has contributed significantly to understanding horizontal gene transfer in asexual species and urban ecosystem impacts on microinvertebrates. Research Interests: Debortoli investigates: (1) Evolutionary dynamics of asexual reproduction in bdelloid rotifers, (2) Genetic hybridization in clam lineages, (3) Environmental DNA metabarcoding for ecological assessment, and (4) Urbanization impacts on microinvertebrate communities. His work integrates genomics, field ecology, and computational biology. Publication Trends: His recent articles (2016-2024) demonstrate a shift from fundamental rotifer genetics toward applied environmental genomics, including SARS-CoV-2 surveillance validation and machine learning applications in hematology. Over 50% of his output addresses sustainable development goals related to aquatic ecosystems and biodiversity conservation.

• Evolutionary Genetics
• Molecular Adaptation
• Asexual Reproduction
• +2 more